This segment focuses on the development of targeted immunotherapies for various cancer types, leveraging the Versamune® platform to enhance T-cell activation and tumor infiltration. Research and development efforts are directed towards PDS0101, a lead product candidate targeting HPV16-associated cancers, and PDS01ADC, an antibody-drug conjugate. Clinical trials are underway to evaluate the efficacy and safety of these therapies in head and neck cancer, cervical cancer, and colorectal cancer. The goal is to improve patient outcomes by stimulating a robust and durable immune response against tumors, offering a potential alternative to traditional cancer treatments. Future opportunities include expanding the pipeline with novel immunotherapeutic approaches and exploring combination therapies to overcome resistance mechanisms.

This segment is dedicated to the development of innovative vaccines for infectious diseases, utilizing the Infectimune® platform to stimulate potent and long-lasting immune responses. Research and development activities are focused on PDS0201 for treating tuberculosis, PDS0202 as an influenza vaccine candidate, and PDS0203 for the prevention of COVID-19. Preclinical studies are conducted to assess the immunogenicity and protective efficacy of these vaccines. The aim is to address unmet medical needs in infectious disease prevention and control, particularly in vulnerable populations. Future opportunities involve expanding the vaccine pipeline to target emerging infectious threats and collaborating with global health organizations to ensure widespread access to these life-saving vaccines.